Neudata Neudata - Alternative Data Intelligence
Email info@neudata.co
  • Solutions

      DATA BUYERS

      New starter

      Build your alternative data program with Neudata

      Experienced data buyer

      Increase the success of your alternative data program

      Compliance focused

      Comply with regulatory requirements while reducing risk

      Private equity & venture capital

      Intelligence through the deal lifecycle

      Professional services

      Level up your data scouting efforts for client projects

      DATA OWNERS

      List your data for free

      Get your data product found by 1,000+ qualified buyers

      Lead generation

      Fill your sales pipeline

      Consulting

      Unlock your data’s profit potential

  • Events
  • About
    • People
    • Careers
    • Press Resources
    • Contact
  • News
  • Sign in
Request a trial

Alternative Data News and Insight

  • All
  • Intelligence
  • Literature Review
  • Signal
  • Tidbits
  • Sentry
  • News
  • Sentry Report
  • Events
  • Blog
  • Trademark activity as a leading economic indicator

    In 2018, we published a piece discussing the potential correlations between trademark registration volume and firm financial performance. But what about the macroeconomic use case? One year later, we investigate whether trademark filing volume can provide an aggregate indicator of business cycle shifts.
    Intelligence 17 Oct 2019
  • Generating Alpha from Pharmaceutical Events using ML & NLP

    The stock market reaction to a single pharmaceutical event, such as a drug approval, repositioning, or adverse event, can have a spillover effect. Beyond the effect on the associated company’s stock price, an event may trigger a latent movement in the stock price of other publicly traded pharmaceutical companies. Research suggests that these sympathetic price movements may be a result of common attributes shared by the companies (beyond economic fundamentals), which are embedded in human language. In this piece, we explore how investors could leverage NLP to detect these ‘hidden relationships’ and generate alpha from pharmaceutical stocks.
    Intelligence 9 Oct 2019
  • Forecasting crop prices using alt data

    In this Intelligence report, we summarise a few alternative datasets that soft commodity investors can leverage in order to predict the prices of crops. Specifically, the report discusses datasets that can offer investors 1) a leading advantage, and/or 2) more visibility into previously opaque regions.
    Intelligence 2 Oct 2019
  • ESG 3.0 – a multilateral alternative data model

    Just because a company says its business practices are ethical, doesn’t necessarily mean they actually are. Recent studies suggest that companies are able to influence their ESG score by greenwashing corporate sustainability information. In this report, we argue that alternative data can be used to test ethical claims as well as build a more accurate and objective ESG risk signal.
    Intelligence 24 Sep 2019
  • Open Banking and Alternative Data

    September 14th was an important milestone in the march towards Open Banking. It marked the original deadline for implementation of PSD2 or ‘the second Payment Services Directive.’ If you don’t know what that is, and you are currently purchasing (or thinking of purchasing) European consumer transactional data – you may want to read on. In this report, we introduce the ubiquitous, yet often poorly understood, FinTech phenomenon of Open Banking, and consider the implications of these regulations on both buyers and sellers of alternative data.
    Intelligence 19 Sep 2019
  • Alternative Data for Healthcare Investors (Part IV): Claims vs EHRs

    In the following Intelligence piece, we explore healthcare claims and electronic health records (EHRs) as alternative data sources for investors. Healthcare claims and EHRs can offer valuable insights into drug/medical device prescribing and utilisation trends. This information has clear applications for investors in pharmaceutical, biotech, and medical device/equipment companies as well as companies responsible for paying healthcare claims such as managed care organisations or other health insurers.
    Intelligence 12 Sep 2019
  • Exposing Accounting Scandals In China Using Alt Data

    Accounting scandals can lead to crippling losses for the uninformed investor - from the Enron and Worldcom scandals to the more recent fraudulent activity of Kangde Xin and Kangmei in China. This article considers the ever-increasing influence of Chinese capital markets, company-level risk factors for financial misreporting, as well as how investors can use alternative data sources to detect early signs of malfeasance by China-listed companies.
    Intelligence 4 Sep 2019
  • An Alternative Data Primer For Telehealth Investors

    Last week, it was announced that leading telehealth provider, Teladoc (NYSE: TDOC), observed a 33% increase in share price and a 40% increase in revenue, year to date. At Neudata, we thought it would be as good a time as any to discuss some alternative datasets that could help investors predict some key metrics of telehealth companies.
    Intelligence 28 Aug 2019
  • Fake News, Fabricated Reviews and the Problem with MAUs

    Didn’t anyone ever tell you that you shouldn’t believe everything you read? In the following intelligence piece, we consider the 21st-century crisis of fabricated content and its implications for users of alternative data. Leave your MAUs at the door and join us in the strange world of app download fraud, review fabrication, and bot-generated content.
    Intelligence 21 Aug 2019
  • How to Profit from FOIA Requests: Investor Case Studies

    We previously highlighted a study which found that institutional investors are using Freedom of Information Act (FOIA) requests – specifically, FDA FOIA requests - to generate abnormal returns. In this piece, we provide three examples of how investors have successfully utilised this FOIA technique to obtain early access to stock-moving information.
    Intelligence 13 Aug 2019
1 … 26 27 28 29 30 31 32 33 34 … 38
Neudata Ltd © 2025. All rights reserved.
  • Terms and Conditions
  • Privacy Statement
  • Cookies